COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,552 Articles (22,400 medRxiv, 8,152 bioRxiv)

Most recent first Previous |  Page 699: Articles 6981-6990  | Next

Population-weighted greenspace exposure tied to lower COVID-19 mortality rates: A nationwide dose-response study
Yang, Y., Lu, Y., Jiang, B.
10.1101/2022.05.24.22275549 — Posted: 2022-05-25
In the Midst of a Pandemic, Introverts May Have a Mortality Advantage
Glei, D. A., Weinstein, M.
10.1101/2022.05.24.22275508 — Posted: 2022-05-25
Toward more realistic social distancing policies via advanced feedback control
Join, C., d'Onofrio, A., Fliess, M.
10.1101/2022.05.25.22275562 — Posted: 2022-05-25
Atovaquone for Treatment of COVID-19: A Prospective Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Jain, M. K., de Lemos, J., McGuire, D. K., Ayers, C., Eiston, J. L., Sanchez, C. L., Kamel, D., Meisner, J. A., Thomas, E. V., Hegde, A. A., Mocherla, S., Strebe, J. K., Li, X., Williams, N. S., Xing, C., Ahmed, M. S., Wang, P., Sadek, H., Schoggins, J. w.
10.1101/2022.05.24.22275411 — Posted: 2022-05-25
A Monte Carlo Estimation of the Narrow-Sense Heritability of COVID-19 Infection and Severity from AncestryDNA Survey Data
Averitt, A. J., Sharma, D., Cantor, M. N.
10.1101/2022.05.23.22275364 — Posted: 2022-05-25
Subcutaneous delivery of an antibody against SARS-CoV-2 from a supramolecular hydrogel depot
Kasse, C. M., Yu, A. C., Powell, A. E., Roth, G. A., Liong, C. S., Jons, C. K., Buahin, A., Maikawa, C. L., Youssef, S., Glanville, J. E., Appel, E. A.
10.1101/2022.05.24.493347 — Posted: 2022-05-25
Covid-19 is a leading cause of death in children and young people ages 0-19 years in the United States
Flaxman, S., Whittaker, C., Semenova, E., Rashid, T., Parks, R., Blenkinsop, A., Unwin, H. J. T., Mishra, S., Bhatt, S., Gurdasani, D., Ratmann, O.
10.1101/2022.05.23.22275458 — Posted: 2022-05-25
Measuring Community Resilience During the COVID-19 based on Community Wellbeing and Resource Distribution
Valinejad, J., Guo, Z., Cho, J.-H., Chen, I.-R.
10.1101/2022.05.23.22275454 — Posted: 2022-05-25
Distinct antigenic properties of the SARS-CoV-2 Omicron lineages BA.4 and BA.5
Willett, B. J., Kurshan, A., Thakur, N., Newman, J., Manali, M., Tyson, G., Logan, N., Murcia, P. R., Snell, L. B., Edgeworth, J. D., Zhou, J., Sukhova, K., Amirthalingam, G., Brown, K., Charleston, B., Malim, M. H., Thomson, E. C., Barclay, W. S., Bailey, D., Doores, K. J., Peacock, T. P.
10.1101/2022.05.25.493397 — Posted: 2022-05-25
Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology
Hemmi, T., Ainai, A., Hashiguchi, T., Tobiume, M., Kanno, T., Iwata-Yoshikawa, N., Iida, S., Sato, Y., Miyamoto, S., Ueno, A., Sano, K., Saito, S., Shiwa-Sudo, N., Nagata, N., Tamura, K., Suzuki, R., Hasegawa, H., Suzuki, T.
10.1101/2022.05.24.493348 — Posted: 2022-05-25

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).